Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Emtricitabine and Tenofovir Alafenamide Fumarate

Home DrugsEmtricitabine and Tenofovir Alafenamide Fumarate

Emtricitabine and Tenofovir Alafenamide Fumarate

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Indications

适用于与其他抗反转录病毒药物联用，治疗成年和青少年(年龄12岁及以上且体重至少为35kg)的人类免疫缺陷病毒1型(HIV-1)感染。

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Pharmaceutical composition comprising emtricitabine, tenofovir and bicotegravir
Applicant: ANHUI BIOCHEM PHARMACEUTICAL CO LTDPriority: 2022
CN
HIV post-exposure prophylaxis
Applicant: US HEALTHPriority: 2018
US